JP2017519008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519008A5 JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
- Authority
- JP
- Japan
- Prior art keywords
- serelaxin
- pharmaceutical formulation
- patient
- biological sample
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 claims 18
- 229960002792 serelaxin Drugs 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 11
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 claims 7
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims 7
- 238000001802 infusion Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010037368 Pulmonary congestion Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011744P | 2014-06-13 | 2014-06-13 | |
| US62/011,744 | 2014-06-13 | ||
| PCT/IB2015/054399 WO2015189790A1 (en) | 2014-06-13 | 2015-06-10 | Use of serelaxin to reduce gdf-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519008A JP2017519008A (ja) | 2017-07-13 |
| JP2017519008A5 true JP2017519008A5 (https=) | 2018-07-19 |
| JP6820748B2 JP6820748B2 (ja) | 2021-01-27 |
Family
ID=53476944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572697A Expired - Fee Related JP6820748B2 (ja) | 2014-06-13 | 2015-06-10 | Gdf−15を減少させるためのセレラキシンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170100460A1 (https=) |
| EP (1) | EP3154559B1 (https=) |
| JP (1) | JP6820748B2 (https=) |
| KR (1) | KR20170018829A (https=) |
| CN (1) | CN106413740A (https=) |
| AU (2) | AU2015273097A1 (https=) |
| BR (1) | BR112016028833A2 (https=) |
| CA (1) | CA2952061A1 (https=) |
| MX (1) | MX2016016414A (https=) |
| RU (1) | RU2016147122A (https=) |
| WO (1) | WO2015189790A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| WO2015077540A2 (en) | 2013-11-21 | 2015-05-28 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| CN106794233B (zh) * | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
| HK1256638A1 (zh) | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| CN114025675A (zh) * | 2019-06-20 | 2022-02-08 | 索尼集团公司 | 信息处理装置、信息处理方法和程序 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511656T1 (de) * | 2006-08-04 | 2011-06-15 | Hannover Med Hochschule | Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis |
| ES2379104T3 (es) * | 2007-05-24 | 2012-04-20 | F. Hoffmann-La Roche Ag | Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15 |
| CN102036679A (zh) * | 2008-05-16 | 2011-04-27 | 科尔泰拉公司 | 用松弛素治疗与急性心力衰竭相关的呼吸困难 |
| EP2726502A1 (en) * | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
-
2015
- 2015-06-10 CN CN201580032028.6A patent/CN106413740A/zh not_active Withdrawn
- 2015-06-10 JP JP2016572697A patent/JP6820748B2/ja not_active Expired - Fee Related
- 2015-06-10 US US15/316,952 patent/US20170100460A1/en not_active Abandoned
- 2015-06-10 WO PCT/IB2015/054399 patent/WO2015189790A1/en not_active Ceased
- 2015-06-10 RU RU2016147122A patent/RU2016147122A/ru not_active Application Discontinuation
- 2015-06-10 BR BR112016028833A patent/BR112016028833A2/pt not_active Application Discontinuation
- 2015-06-10 AU AU2015273097A patent/AU2015273097A1/en not_active Abandoned
- 2015-06-10 CA CA2952061A patent/CA2952061A1/en not_active Abandoned
- 2015-06-10 KR KR1020167034407A patent/KR20170018829A/ko not_active Withdrawn
- 2015-06-10 MX MX2016016414A patent/MX2016016414A/es unknown
- 2015-06-10 EP EP15730858.6A patent/EP3154559B1/en not_active Not-in-force
-
2018
- 2018-03-29 AU AU2018202289A patent/AU2018202289A1/en not_active Abandoned
- 2018-09-21 US US16/137,770 patent/US20190022189A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519008A5 (https=) | ||
| Guo et al. | Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation | |
| Ingenbleek et al. | Plasma transthyretin as a biomarker of lean body mass and catabolic states | |
| Mondal et al. | Stress hyperglycemia ratio, rather than admission blood glucose, predicts in-hospital mortality and adverse outcomes in moderate-to severe COVID-19 patients, irrespective of pre-existing glycemic status | |
| Yanishi et al. | Factors associated with the development of sarcopenia in kidney transplant recipients | |
| Grodin et al. | Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF | |
| Behr | The diagnosis and treatment of idiopathic pulmonary fibrosis | |
| Peck-Radosavljevic et al. | Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) | |
| Karavanaki et al. | Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis | |
| JP2015501297A5 (ja) | 医薬組成物、方法、診断キット | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| JP2016520573A5 (https=) | ||
| Zhang et al. | The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism | |
| Lin et al. | Preliminary prospective study to assess the effect of early blood urea nitrogen/creatinine ratio-based hydration therapy on poststroke infection rate and length of stay in acute ischemic stroke | |
| Lazzeri et al. | Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization | |
| Nazim et al. | Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes | |
| de Almeida Faro et al. | Left ventricular hypertrophy in children, adolescents and young adults with sickle cell anemia | |
| Sato et al. | Therapeutic targets and early stage clinical trials for pulmonary fibrosis | |
| Gores et al. | Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy | |
| Sharma et al. | Alveolar macrophage activation in obese patients with obstructive sleep apnea | |
| Csobay-Novák et al. | Decreased plasma nociceptin/orphanin FQ levels after acute coronary syndromes | |
| Rouini et al. | Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage | |
| Kaman et al. | Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support | |
| Yamaguchi et al. | A case of severe hypothyroidism causing cardiac tamponade associated with lithium intoxication | |
| Shinohara et al. | Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance |